MSN Laboratories Pvt. Ltd. can’t reopen disputes resolved in earlier litigation over the scope, validity, and infringement of ...

A federal judge in New Jersey denied a preliminary injunction sought by Novartis (NYSE:NVS) to block MSN Pharmaceuticals from launching a generic version of the former’s blockbuster heart failure ...

After more than six years of high-stakes litigation in multiple courts and regulatory fights at the Food and Drug Administration (FDA), generic versions of Novartis Pharmaceuticals Corp.

The Third Circuit and Federal Circuit this week turned back Novartis’s requests for injunctions to block a version of its heart failure medication Entresto from generic maker MSN ...

After Novartis’ patent on the blockbuster blood pressure medication Entresto was found invalid at the district court for covering technology that was developed after the patent was filed, the Federal ...

Fast growth for recently label-expanded drugs fuelled Novartis’ Q3 performance, despite headwinds from generic competition affecting more established blockbusters. Net sales for the Swiss big pharma ...

FILE PHOTO: The company's logo is seen at a building of Swiss drugmaker Novartis in Rotkreuz, Switzerland, January 29, 2020. REUTERS/Arnd Wiegmann/File Photo FRANKFURT (Reuters) -Swiss drugmaker ...

FRANKFURT (Reuters) -Swiss drugmaker Novartis met third-quarter profit forecasts on Tuesday, as fast growth of newer drugs offset a sharp slowdown in blockbuster heart drug Entresto as it comes under ...

FRANKFURT (Reuters) -Swiss drugmaker Novartis, on a deal-making spree this year, reported a 6% gain in operating income as growth of its new drugs outpaced stagnant revenue from established heart drug ...